Review · Volume 14, Issue 3 · pp. 532–540
Unveiling Tigliane Derivatives as Novel Therapeutics for Alzheimer's Disease
Kausik Bhar1, Sumanta Mondal2, Kazi Asraf Ali3, Saptarshi Samajdar1
- 1Department of Pharmaceutical Technology, Brainware University, Barasat, Kolkata, West Bengal, INDIA.
- 2Department of Pharmaceutical Chemistry, School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, INDIA.
- 3Department of Pharmaceutical Technology, Maulana Abul Kalam Azad University of Technology, West Bengal, Nadia, West Bengal, INDIA.
Abstract
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder with limited therapeutic options. Current treatments offer only symptomatic relief without halting disease progression. Natural products and their derivatives have garnered increasing interest for neuroprotection. Among them, tigliane diterpenoids, primarily derived from the Euphorbiaceae family, have shown potent biological activities, including anti-inflammatory, antioxidant, and neuroprotective properties. This review examines the therapeutic potential of tigliane derivatives in the treatment of Alzheimer's disease, concentrating on their pharmacological effects, molecular mechanisms, and structure-activity relationships. Furthermore, we discuss challenges and prospects of tigliane-based drug development as novel interventions for AD.
Keywords: Tigliane; Alzheimer's disease; Neuroinflammation; Antioxidant; Amyloid-β; Diterpenoids; Protein Kinase C
The full text of this article is available as a PDF. Open the PDF.